Clinical Trial Update: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of MLN0128 (TAK-228) and AZD9291 in EGFR mutation-positive advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib) (osimertinib)
• MLN0128 (TAK-228) (MLN0128)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING